Midway Pharmaceuticals, Inc.
2 Pump House
Spring House, PA 19477
Contact: Rifat Pamukcu, MD, CEO
Tel: 215-628-0938
r.pamukcu AT midwaypharma.com

• $1.9M invested to date
• Seeking up to $7M Series A Round

Current Investors:
• BioAdvance
• Ben Franklin Technology Partners
• University of Chicago
• Founders & Angels

Use of Proceeds:
• $1.5 M to complete preclinical safety testing and achieve GRAS designation
• $5 M for clinical trial supporting marketing claims in bone health
• Exit/Partnering Points Begin:
• Expected within 30-36 months

Competitive Advantages:
• Proprietary food ingredient covered by worldwide patent applications
• Unique mechanism blocks pathogenic bacteria and preserves gut integrity
• Low cost of goods (pennies per day)
• Odorless, tasteless and colorless material combinable with wide range of foods
• Strong interest from potential partners seeking new dietary supplements

Midway Pharmaceuticals is an emerging specialty pharmaceutical company focused on developing new drugs for the treatment of gastrointestinal and systemic disorders. Our technology is particularly useful for those disorders caused or influenced by gastrointestinal barrier dysfunction and bacteria. We have demonstrated beneficial effects in a range of animal models and are making preparations to begin clinical develoment of our lead product.

Midway Pharmaceuticals